Literature DB >> 8981459

Comparison of nociceptive effects produced by intrathecal administration of mGluR agonists.

K Fisher1, T J Coderre.   

Abstract

The present study examined the mGluR subtypes involved in (1S, 3R)-ACPD-induced spontaneous nociceptive behaviours (SNB) by administering the following selective agonists by the intrathecal (i.t.) route: (RS)-DHPG, trans-ADA (Group I; mGluR1/5 and mGluR5, respectively), (1S, 3S)-ACPD, (2R, 4R)-APDC (Group II), and L-AP4 (Group III). (RS)-DHPG administration induced SNB that were of significantly greater intensity and longer duration than those induced by an equal dose of (1S, 3R)-ACPD. No other agonists produced SNB, except (1S, 3S)-ACPD, which may be attributable to a nonselective action at mGluR1. Intrathecal treatment with the mGluR antagonist (+)-MCPG or the NMDA antagonist D-AP5 prior to (RS)-DHPG administration dose-dependently reduced SNB. It is suggested that a possible interaction between NMDA and mGluR1 is a critical event in the maintenance of persistent nociception.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8981459     DOI: 10.1097/00001756-199611040-00067

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  20 in total

1.  Metabotropic glutamate receptor subtypes 1 and 5 are activators of extracellular signal-regulated kinase signaling required for inflammatory pain in mice.

Authors:  F Karim; C C Wang; R W Gereau
Journal:  J Neurosci       Date:  2001-06-01       Impact factor: 6.167

2.  Involvement of metabotropic glutamate receptor 5 in pudendal inhibition of nociceptive bladder activity in cats.

Authors:  Jeffrey A Larson; P Dafe Ogagan; Guoqing Chen; Bing Shen; Jicheng Wang; James R Roppolo; William C de Groat; Changfeng Tai
Journal:  J Physiol       Date:  2011-10-17       Impact factor: 5.182

3.  Knockdown of spinal metabotropic glutamate receptor 1 (mGluR(1)) alleviates pain and restores opioid efficacy after nerve injury in rats.

Authors:  M E Fundytus; K Yashpal; J G Chabot; M G Osborne; C D Lefebvre; A Dray; J L Henry; T J Coderre
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 4.  Glutamate receptors and nociception: implications for the drug treatment of pain.

Authors:  M E Fundytus
Journal:  CNS Drugs       Date:  2001-01       Impact factor: 5.749

Review 5.  Current and Future Issues in the Development of Spinal Agents for the Management of Pain.

Authors:  Tony L Yaksh; Casey J Fisher; Tyler M Hockman; Ashley J Wiese
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 6.  Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics.

Authors:  Nebojsa Nick Knezevic; Ajay Yekkirala; Tony L Yaksh
Journal:  Anesth Analg       Date:  2017-11       Impact factor: 5.108

7.  The Role of Type 1 Metabotropic Glutamate Receptors in the Generation of Dorsal Root Reflexes Induced by Acute Arthritis or the Spinal Infusion of 4-Aminopyridine in the Anesthetized Rat.

Authors:  Li Ping Zhang; Ying Chen; Barry P Clark; Emanuele Sher; Karin N Westlund
Journal:  J Pain       Date:  2000       Impact factor: 5.820

8.  Antisense ablation of type I metabotropic glutamate receptor mGluR1 inhibits spinal nociceptive transmission.

Authors:  M R Young; G Blackburn-Munro; T Dickinson; M J Johnson; H Anderson; I Nakalembe; S M Fleetwood-Walker
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

9.  Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia.

Authors:  Rita Nyilas; Laura C Gregg; Ken Mackie; Masahiko Watanabe; Andreas Zimmer; Andrea G Hohmann; István Katona
Journal:  Eur J Neurosci       Date:  2009-05-09       Impact factor: 3.386

10.  Signal transduction mechanisms underlying group I mGluR-mediated increase in frequency and amplitude of spontaneous EPSCs in the spinal trigeminal subnucleus oralis of the rat.

Authors:  Ji-Hyeon Song; Eun-Sung Park; Sang-Mi Han; Seung-Ro Han; Dong-Kuk Ahn; Dong-Ho Youn
Journal:  Mol Pain       Date:  2009-09-02       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.